Stillbirth
Conditions
Keywords
stillbirth, cerebroplacental ratio, fetal growth restriction
Brief summary
The purpose of this study is to evaluate the role of an integrated strategy at selecting fetuses for delivery at term based on a combination of fetal biometry and cerebroplacental ratio (CPR) to reduce stillbirth rate and adverse perinatal outcome.
Detailed description
This is a multicenter, open-label randomized trial with groups in parallel. Singleton pregnancies are recruited after routine second trimester scan (19+0 to 22+6 weeks of gestation) and randomly allocated at that moment to revealed or concealed strategy. A routine scan will be booked at 36-37 weeks. For a reduction of the stillbirth rate of 3‰ (from 5‰ to 2‰), assuming a type I error of 5% and aiming for a power of 80% a total of 11,582 subjects (5791 per arm) were projected. The participating centers sum up 12,000 deliveries a year. It is not possible to blind participants, obstetricians, or outcome assessors to the study group. General hypothesis: A proportion of fetuses with normal growth as per current standards have placental insufficiency and restriction of their growth potential. These fetuses exhibit biophysical changes expressed by abnormal cerebroplacental ratio. A combination of this marker with fetal biometry for the detection of fetuses affected by fetal growth restriction could identify a group of babies on which labor induction once term is reached may prevent the occurrence of adverse outcomes. Specific hypothesis * The cerebroplacental ratio has predictive value in late pregnancy for placental insufficiency. * The cerebroplacental ratio could improve the effectiveness of late pregnancy screening for the prediction placental insufficiency-related complications.
Interventions
Cerebroplacental ratio revealment
Sponsors
Study design
Eligibility
Inclusion criteria
* Viable singleton non-malformed fetus * Available first-trimester US dating * Maternal age at recruitment ≥18 years * No adverse medical or obstetrical history at booking * Capacity to give informed consent
Exclusion criteria
* Abnormal karyotype * Structural abnormalities * Congenital infections
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Stillbirth | between 37 and 42 weeks of pregnancy | Perinatal death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse perinatal outcome | Up to 28 days after delivery | Severe neurological and non-neurological adverse outcome |
| Fetal Growth Restriction Detection | 3 years | To detect prenatal low birth weight |
Countries
Chile, Czechia, Israel, Mexico, Poland, Spain